Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

Press release

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

rehaneo, a leading provider of outpatient rehabilitation, aftercare, prevention, and occupational health management founded in 2020, welcomes Fremman Capital to its shareholder base. Fremman takes over the majority shareholding previously held by the European investment company Gimv. Founder and CEO Bruno Crone and co-founder and COO Christoph Dühr remain significantly invested in the company and continue their management roles.

Since its founding four years ago, during the peak of the COVID-19 pandemic, Gimv and the managing rehaneo shareholders Bruno Crone and Christoph Dühr have successfully built the company into one of the top three providers in the field of outpatient rehabilitation through a successful buy-and-build strategy. Since 2023, Dr. Alain Robbe-Grillet completes the management team as CFO.

To date, rehaneo has integrated 13 companies at 23 locations nationwide into the group, including some of the leading facilities in Germany. Recently, rehaneo also opened a completely new center in Göttingen.

The rehaneo group now employs over 1,000 staff who are dedicated to the care of more than 80,000 patients and customers annually. The range of services offered by the centers varies by location, from outpatient rehabilitation and rehab aftercare to physiotherapy and occupational therapy, as well as prevention and fitness. In addition to developing locations and the continuous growth of the group, the focus is primarily on the quality of services. This is ensured, among other things, by a medical board with renowned experts, including Prof. Dr. med. Thomas Wessinghage. rehaneo aims to further densify the care network and offer more people professional rehabilitation close to their homes. 

Outpatient rehabilitation costs are significantly lower than inpatient stays, benefiting the healthcare system. Additionally, there is increasing demand from patients who want to stay in their familiar environment during rehabilitation. Together with Fremman, the management team intends to continue the successful growth strategy, accelerating M&A and consolidating further a very fragmented sector, to create a European leader.

Bruno Crone, Founder and CEO of the rehaneo group, declares: “We thank Gimv for their active support and the trustful cooperation from the beginning, which made it possible to become one of the leading quality providers in outpatient rehabilitation in such a short time. We are excited to start a new chapter of our success story with Fremman. Our focus will be on acquiring new outpatient rehab centers and the strategic development of existing facilities and the entire group.”

Mirko Meyer-Schönherr and Max Schürenkrämer, Founding Partner and Managing Director at Fremman, add: “We are very impressed by the development of the rehaneo group so far and see great potential in the outpatient rehabilitation sector. We look forward to supporting the experienced and ambitious rehaneo management team in

further developing the strategy of the group.”

Philipp von Hammerstein and Lars Timmer, Partner and Principal at Gimv Healthcare, comment: “We are proud that together with rehaneo, we have built a leading company and competent partner in outpatient care in just four years, distinguished by high customer and patient satisfaction as well as high-quality standards.”

Gimv NV - Karel Oomsstraat 37, 2018 Antwerp, Belgium - T +32 3 290 21 00 - www.gimv.com                                                                                   1

Munich (DE) & Antwerp (BE), 20 November 2024, 07:45 CET   Press release

The transaction is subject to approval by the German antitrust authorities and is expected to close in Q1 2025. This transaction will have a positive impact on our NAV at 30 September 2024, as will be published on 21 November next, of around EUR 1 per share. The realized return on this transaction substantially exceeds our long-term portfolio return target.

About Gimv

Gimv is a European investment company, listed on Euronext Brussels and a member of the Euronext BEL ESG Index. With over 40 years' experience in private equity, Gimv currently has an investment portfolio of more than EUR 1.5 billion. The portfolio contains around 60 portfolio companies, with combined turnover of EUR 4.0 billion and more than 20,000 employees.

As a recognized market leader in selected investment   platforms,               Gimv       identifies entrepreneurial, innovative companies with high growth potential and supports them in their transformation into market leaders. Gimv's five investment platforms are Consumer, Healthcare, Life Sciences, Smart Industries and Sustainable Cities. Each platform works with an experienced team across Gimv’s home markets of Benelux, France and DACH, supported by an extended international network of experts.

Further information on Gimv can be found on www.gimv.com.

For further information please contact:

Bart Diels, Managing Partner - Head of Healthcare T +32 +32 3 290 21 58 bart.diels@gimv.com 

Philip von Hammerstein, Partner Healthcare T +49 89 44 23 275 10 philipp.vonhammerstein@gimv.com

Gimv NV - Karel Oomsstraat 37, 2018 Antwerp, Belgium - T +32 3 290 21 00 - www.gimv.com                                                                                   2